Tetragon Biosciences Launches Phase 1 Trial of TET2 Agonist GLIX1 in Recurrent Glioblastoma

Tetragon Biosciences has opened a [Phase 1 clinical trial](https://clinicaltrials.gov/study/NCT07464925) of GLIX1, an oral small molecule that agonizes TET2, in adults with recurrent or progressive high-grade glioma including glioblastoma. The trial, which received FDA IND clearance in August 2025, marks the first time a direct TET2 agonist has entered human testing in any indication. GLIX1 also holds Orphan Drug Designation from both the FDA and the EMA for malignant glioma. No new systemic therapy has been approved for recurrent glioblastoma since bevacizumab in 2009, and that agent showed no overall survival benefit in randomized trials. The field's failure rate in late-stage development exceeds 95%, making any first-in-class mechanism entering the clinic a closely watched event. The open-label, multicenter study (NCT07464925) plans to enroll approximately 30 participants across Northwestern Medicine, Moffitt Cancer Center, and NYU Langone Health. It uses a Bayesian Optimal Interval design to guide dose escalation, starting at 1,000 mg/day administered orally as capsules in 28-day cycles. The co-primary endpoints are the proportion of participants with treatment-emergent adverse events graded by CTCAE v6.0 and identification of a maximum tolerated dose, defined as the dose at which the isotonic estimate of the dose-limiting toxicity rate is closest to a target of 0.3, assessed during the first 28-day cycle. Eligible patients must be aged 18 or older with histologically confirmed Grade 3 or Grade 4 glioma, ECOG performance status of 0 or 1, and no more than two prior treatment lines. A dose-expansion cohort will follow escalation. Primary completion is anticipated in Q2 2027, with overall study completion projected for Q4 2027. GLIX1 was originated by Hemispherian AS, a Norwegian biotech, and is being advanced through a joint venture with BioLineRx Ltd. under the Tetragon Biosciences entity that sponsors the trial. The molecule enhances TET2 enzymatic activity, increasing oxidation of 5-methylcytosine residues. The resulting oxidized bases are processed by base excision repair, generating single-strand DNA breaks. In normal cells these breaks are tolerated, but in cancer cells — where aberrant hypermethylation clusters modified cytosines in close genomic proximity — the simultaneous repair events converge into double-strand breaks that exceed repair capacity and trigger apoptosis. High-grade gliomas exhibit among the lowest genomic levels of 5-hydroxymethylcytosine of any tumor type, indicating suppressed TET2 function and dense hypermethylation, which provides the biological rationale for testing GLIX1 in this population. Preclinical data cited in the trial record indicate that GLIX1 crosses the blood-brain barrier in rodent models and showed activity in in vitro and in vivo glioblastoma models, though peer-reviewed publications of these data have not yet appeared ([Treatment options for glioblastoma](https://app.allsci.com/article/W2108301172)). The recurrent glioblastoma pipeline is active yet littered with failures. Dordaviprone (ONC201, Chimerix), a DRD2 antagonist and ClpP agonist, is in Phase 3 for H3K27M-mutant diffuse midline glioma and carries Breakthrough Therapy Designation, though it targets a molecular subtype distinct from GLIX1's broader high-grade glioma population. Paxalisib (Kazia Therapeutics), a brain-penetrant PI3K/mTOR inhibitor, is in Phase 2 for MGMT-unmethylated glioblastoma. Regorafenib (Bayer) showed an overall survival signal versus lomustine in the Phase 2 REGOMA trial and is being evaluated in the GBM AGILE adaptive platform. Checkpoint inhibitors including nivolumab (Bristol-Myers Squibb) failed across three Phase 3 glioblastoma trials. GLIX1 is differentiated by its first-in-class TET2 agonist mechanism, oral bioavailability, demonstrated preclinical blood-brain barrier penetration, and a rationale independent of MGMT methylation or IDH mutation status — molecular features that constrain the applicability of several competing agents such as vorasidenib (Servier), which is approved only for Grade 2 IDH-mutant glioma ([Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment](https://app.allsci.com/article/W4402051434)). Tetragon Biosciences GLIX1 Phase 1 trial tests first-in-class oral TET2 agonist in recurrent high-grade glioma patients. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/tet2-agonist-glix1-tetragon-biosciences-launches)